Is Coya Therapeutics, Inc. (COYA) a Buy, Sell, or Hold?
NASDAQ : COYA
Coya Therapeutics, Inc.
$4.265 USD
$0.01 (0.35%)
- Volume
- 81.06K
- Average Volume
- 205.18K
- Market Capitalization
- $77.66M
- P/E Ratio
- -3.71
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $7.75
- Year Low
- $3.71
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.02
Company Overview
NASDAQ
Arun Swaminathan
Biotechnology
Healthcare
COYA
8
US
USD
Liquidity Metrics
0.00
15.02
15.02
14.30
0.00
Sales & Valuation
$7.95M
9.78
1.46
-5.50
-0.84
Profitability
-$1.27
-$21.23M
-266.11%
-266.07%
-57.26%
-39.66%
P/E Metrics
-3.71
0.29
0.29
Analyst Price Target & Rating
$12.00
$12.00
$12.00
1/5
5 Analysts
-64.46%
Financial Health Scores
8.94
4/9
$49.72M
$53.27M
$4.3M
-$21.12M
Key Metrics (TTM)
$26.66M
3.36
-1.26
15.02
-57.26%
-44.23%
-29.71%
-18.25%
-20992 days
Company Executives
| Name | Title |
|---|---|
| David S. Snyder | Chief Financial Officer & Chief Operating Officer |
| Fred Grossman FAPA | President & Chief Medical Officer |
| Michelle Frazier | Senior Vice President of Regulatory |
| Aaron Thome | Head of Neuroinflammation Platform |
| Karen King | Senior Vice President of Program Management & Clinical Operations |
| Arun Swaminathan | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Coya Therapeutics, Inc. (NASDAQ:COYA) Stock
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable ... for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
2026-06-30 10:41:22
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
2026-06-18 09:00:00
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
2026-06-18 08:00:00
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the European Network to Cure ALS (ENCALS) Meeting 2026 which will take place June 24–26, 2026, in Madrid, S.
2026-06-15 09:00:00
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
2026-06-15 08:00:00
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 p.m. PT. Titled ‘Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect', the webinar will explore the relationship between repetitive he.
2026-06-08 08:00:00
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (ClinicalTrials.gov Identifier: NCT07161999). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the first phase; placebo patients a.
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
2026-05-27 08:00:00
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2–4, 2026, in Boston, MA. The details for th.
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-12 07:35:00
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. “We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year,” said Arun Swaminathan, Ph.D., Chief Executive O.
Frequently Asked Questions
-
What is the current Coya Therapeutics, Inc. (COYA) stock price?
-
Coya Therapeutics, Inc.(NASDAQ:COYA) stock price is $4.265 in the last trading session. During the trading session, COYA stock reached the peak price of $7.75 while $3.71 was the lowest point it dropped to. The percentage change in COYA stock occurred in the recent session was 0.35% while the dollar amount for the price change in COYA stock was $0.01.
-
COYA's industry and sector of operation?
-
The NASDAQ listed COYA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of COYA?
-
David S. Snyder | Chief Financial Officer & Chief Operating Officer
Fred Grossman FAPA | President & Chief Medical Officer
Michelle Frazier | Senior Vice President of Regulatory
Aaron Thome | Head of Neuroinflammation Platform
Karen King | Senior Vice President of Program Management & Clinical Operations -
How many employees does COYA have?
-
Number of COYA employees currently stands at 8. COYA operates from 5850 San Felipe Street, Houston, TX 77057, US.
-
Link for COYA official website?
-
Official Website of COYA is: https://www.coyatherapeutics.com
-
How do I contact COYA?
-
COYA could be contacted at phone #800-587-8170 and can also be accessed through its website. COYA operates from 5850 San Felipe Street, Houston, TX 77057, US.
-
How many shares of COYA are traded daily?
-
The average number of COYA shares traded daily for last 3 months was 205.18K.
-
What is the market cap of COYA currently?
-
The market value of COYA currently stands at $77.66M with its latest stock price at $4.265